AIMD
Ainos, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.84
P/S
51.38
EV/EBITDA
-1.83
DCF Value
$-2.66
FCF Yield
-72.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.9%
Operating Margin
-11268.3%
Net Margin
-11897.0%
ROE
-140.1%
ROA
-70.8%
ROIC
-70.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $11.1K | $-4.5M | $205.32 |
| FY 2025 | $124.2K | $-14.8M | $-3.46 |
| Q3 2025 | $2.2K | $-2.9M | $-0.64 |
| Q2 2025 | $4.7K | $-4.1M | $-0.99 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.38
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.